The future of NL research
Clinical trials for rare diseases are uncommon in general, not just in the case of neurolymphomatosis. But, it’s important not to give up hope that clinical trials, and ultimately a standardized treatment plan, might one day happen. As more lymphoma patients present with the condition, the more physicians will be able to understand about NL and ultimately have a deep enough understanding to design the basis of a clinical trial. And, top research institutions are aware of the problem. The National Institutes of Health (NIH) has efforts in place to increase the amount of research completed and funds allocated to rare diseases. More information on clinical trials can be found here.